Immunology

NORTH CHICAGO, Ill., June 7, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-NEXT clinical trial evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis (RA) who did not adequately respond to treatment with conventional synthetic DMARDs (csDMARDs).¹ Results showed that after 12 weeks of treatment, both doses of upadacitinib (15 mg and 30 mg) met the study's primary endpoints of ACR20 and low disease activity.¹ Key secondary endpoints were also achieved and included ACR50, ACR70 and clinical remission.¹ Full results will be presented at an upcoming medical meeting and published in a peer-reviewed publication. Upadacitinib is an investigational oral agent and is not approved by regulatory authorities.

NORTH CHICAGO, Ill., May 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced promising results from CELEST, a Phase 2, randomized, double-blind, placebo-controlled study evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in adult patients with moderately to severely active Crohn's disease. These data are being presented today during the Clinical Science: Late-Breaking Abstract Plenary Session (Presentation #874h) at Digestive Disease Week® 2017.

NORTH CHICAGO, Ill., March 30, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in the HUMIRA® (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis. HUMIRA is now the first-and-only biologic treatment with data on fingernail psoriasis in its U.S. prescribing information.

 - Orphan Drug Designation program provides orphan status to medications intended for the safe and effective treatment, diagnosis or prevention of rare diseases[1]

NORTH CHICAGO, Ill., Nov. 14, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA® (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy. If approved, HUMIRA will become the first and only biologic treatment option for patients 12 years of age and older. HUMIRA was approved for adults with moderate to severe HS by the European Commission in July 2015. 

NORTH CHICAGO, Ill., Sept. 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that new data on HUMIRA® (adalimumab) and investigational medicine risankizumab (formerly BI 655066), an IL-23 inhibitor, will be presented at the 25^th European Academy of Dermatology and Venereology Congress (EADV), September 28 - October 2, in Vienna, Austria. These presentations build upon AbbVie's continued scientific leadership in serious dermatological conditions including psoriasis, psoriatic arthritis and hidradenitis suppurativa.

NORTH CHICAGO, Ill., July 19, 2016 /PRNewswire/ -- World-renowned soccer player Brandi Chastain today announced her partnership with AbbVie, a global biopharmaceutical company, on the new educational program, My IBD Game Plan. The program is designed to help individuals living with Crohn's disease and ulcerative colitis, the two most common forms of inflammatory bowel disease (IBD), create a plan to help manage everyday life with these diseases. Inflammatory bowel disease affects as many as 1.6 million Americans.¹ The resources on the program website, www.IBDGamePlan.com, will help people living with IBD and their caregivers proactively work with their healthcare providers and support team to take control and manage the symptoms of these diseases.

The brain’s protection barrier prevents medicines from getting in, but new approaches are finding ways to bust through and treat central nervous system diseases.